Caplin Point Laboratories

2,006.00
+3.60
(0.18%)
ann
There are new updates from the company22 hours ago
Viewcross
right
Market Cap
15,247.95 Cr
EPS
70.57
PE Ratio
28.37
Dividend Yield
0.27 %
Industry
Healthcare
52 Week High
2,641.00
52 Week Low
1,408.00
PB Ratio
5.34
Debt to Equity
0.00
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,678.70
#1 4,02,776.36
35.11
#1 52,041.20
12.06
#1 10,980
-18.99
49.60
6,915.00
1,83,571.52
83.20
9,360.00
0.89
2,117
23.05
67.24
1,516.20
1,22,464.66
23.68
28,409.50
7.12
5,291
30.28
52.75
3,377.50
1,14,309.95
58.56
11,317.00
11.59
2,054
10.91
59.08
1,290.90
1,07,734.78
19.45
33,741.20
12.36
5,725
21.14
49.51
1,004.40
1,01,066.14
21.53
22,573.80
13.82
3,977
-0.19
69.48
2,420.80
99,913.38
49.11
12,207.40
19.57
1,925
-10.91
49.97
1,983.00
90,562.71
27.22
22,192.10
#1 19.94
3,024
#1 112.49
47.26
35,410.00
75,243.78
53.31
6,409.15
10.80
1,417
27.83
71.69
1,175.70
68,284.85
#1 19.42
31,378.10
17.55
3,366
-0.50
55.14

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
15.65 %
Net Income Growth
22.39 %
Cash Flow Change
17.33 %
ROE
-0.56 %
ROCE
1.57 %
EBITDA Margin (Avg.)
7.57 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
64
71
78
81
84
87
98
105
122
127
135
144
146
148
163
167
190
197
234
239
235
247
270
280
288
310
312
336
351
360
376
386
401
407
431
453
471
478
504
524
528
Expenses
48
51
57
57
61
63
68
71
75
78
82
91
95
93
100
101
123
125
156
160
161
169
181
191
193
208
202
225
239
244
254
263
265
269
273
293
308
307
318
331
334
EBITDA
16
20
22
24
22
24
30
34
48
50
53
53
52
55
63
66
67
72
78
78
73
78
89
90
95
102
110
111
111
116
122
124
135
139
158
160
163
170
185
194
194
Operating Profit %
24 %
27 %
27 %
29 %
25 %
26 %
29 %
31 %
37 %
37 %
38 %
36 %
34 %
36 %
36 %
36 %
35 %
35 %
31 %
30 %
25 %
30 %
33 %
31 %
31 %
31 %
33 %
31 %
29 %
30 %
29 %
29 %
32 %
32 %
34 %
33 %
32 %
33 %
34 %
33 %
33 %
Depreciation
1
3
2
3
3
3
3
3
5
4
4
5
6
5
6
6
7
7
7
8
8
9
9
9
10
12
12
12
11
11
12
11
11
11
12
14
16
16
17
16
17
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
15
16
20
21
20
21
27
31
43
46
49
49
45
49
57
60
61
64
71
70
65
69
80
80
85
90
98
99
100
105
110
112
124
127
146
145
146
154
169
177
177
Tax
4
4
5
5
4
5
5
7
9
10
13
11
10
12
14
14
11
14
13
11
16
14
17
14
17
18
21
19
19
19
18
14
23
23
30
26
25
30
38
37
31
Net Profit
11
13
14
16
16
16
22
24
33
36
36
38
35
37
44
46
50
50
57
59
49
55
63
66
68
72
77
79
81
86
92
97
101
104
116
120
121
125
131
140
145
EPS in ₹
7.02
8.40
1.86
10.66
10.31
10.55
14.85
3.15
4.41
4.81
4.71
4.97
4.76
4.95
6.21
6.06
6.58
6.64
7.58
7.74
6.46
7.21
7.52
8.52
8.78
9.37
9.91
9.90
10.43
11.21
12.09
12.86
13.45
13.62
15.13
15.44
16.01
16.32
17.22
18.28
18.75

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
229
267
358
501
743
1,126
1,364
1,736
2,191
2,698
3,209
Fixed Assets
113
144
152
170
227
273
305
287
280
453
689
Current Assets
82
119
179
304
494
823
1,015
1,298
1,552
1,893
2,134
Capital Work in Progress
31
0
3
15
10
20
14
18
221
117
139
Investments
0
0
17
47
70
61
11
89
281
376
336
Other Assets
85
123
186
269
436
772
1,033
1,343
1,410
1,753
0
Total Liabilities
229
267
358
501
743
1,126
1,364
1,736
2,191
2,698
3,209
Current Liabilities
125
125
113
109
86
144
143
208
268
331
306
Non Current Liabilities
10
14
20
28
23
25
17
19
16
20
16
Total Equity
94
128
225
364
633
957
1,203
1,510
1,907
2,347
2,851
Reserve & Surplus
78
113
210
349
514
716
954
1,252
1,649
2,084
2,835
Share Capital
15
15
15
15
15
15
15
15
15
15
15

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
19
23
25
-14
74
70
215
-81
27
-39
Investing Activities
-23
-6
-36
-69
-100
-54
-30
-377
-216
-319
Operating Activities
50
42
68
67
83
45
269
337
271
318
Financing Activities
-9
-14
-7
-12
90
80
-24
-41
-28
-38

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 1.5 2 2.2 2.5 3 4 4.5 5 0.00
Dividend Yield (%) 0.00 0.26 0.5 0.78 0.62 0.44 0.68 0.34 0.25 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 May 2025 DIVIDEND Dividend
₹ 3.00 /share
30 May 2025 2,000.05 2,152.60
15 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
15 May 2025 1,861.85 2,000.05
07 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Feb 2025 2,079.25 2,216.50
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 1,979.35 2,117.50
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2024 1,579.70 1,897.95
23 Sept 2024 DIVIDEND Dividend
₹ 2.50 /share
23 Sept 2024 1,579.70 1,902.85
31 May 2024 DIVIDEND Dividend
₹ 2.50 /share
31 May 2024 1,363.80 1,289.65
14 Sept 2023 DIVIDEND Dividend
₹ 2.50 /share
14 Sept 2023 896.45 1,032.00
09 Jun 2023 DIVIDEND Dividend
₹ 2.00 /share
09 Jun 2023 736.75 800.30
22 Sept 2022 DIVIDEND Dividend
₹ 2.00 /share
21 Sept 2022 822.00 730.75
24 May 2022 DIVIDEND Dividend
₹ 2.00 /share
23 May 2022 662.65 733.70
21 Sept 2021 DIVIDEND Dividend
₹ 1.50 /share
20 Sept 2021 913.95 873.55
19 May 2021 DIVIDEND Dividend
₹ 1.50 /share
18 May 2021 560.30 588.85

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 201822 hours ago
Closure of Trading Window6 days ago
Announcement under Regulation 30 (LODR)-Change in Management6 days ago
Announcement under Regulation 30 (LODR)-Newspaper Publication7 days ago
Announcement under Regulation 30 (LODR)-AcquisitionJun 04, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
Corporate Action-Board approves DividendMay 15, 2025
The Record Date For Declaration Of Interim Dividend Is Fixed At May 30 2025. The Details Of The Same Is Attached Herewith.May 15, 2025
The Board Had Approved Interim Dividend For The Year Ended 31-03-2025 Along With The Audited Results. The Details Of The Same Is Enclosed Herewith.May 15, 2025
Board Meeting Outcome for The Board Had Approved Interim Dividend For The Year Ended 31-03-2025 Along With The Audited Results. The Details Of The Same Is Enclosed Herewith.May 15, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
Announcement under Regulation 30 (LODR)-CessationMay 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 07, 2025
Board Meeting Intimation for Financial Results And Declaration Of Interim Dividend If Approved By The Board.May 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 23, 2025
Announcement under Regulation 30 (LODR)-CessationApr 21, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Announcement under Regulation 30 (LODR)-AcquisitionApr 02, 2025
Cautionary Letter From NSE And BSE On March 28 2025Mar 29, 2025
Closure of Trading WindowMar 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 07, 2025
Integrated Filing (Financial)Feb 07, 2025
Board Meeting Outcome for Board Meeting Outcome Of The Financial Results For The Quarter Ended December 31 2024Feb 07, 2025
Financial Results For The Quarter Ended December 31 2024Feb 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 31, 2025
Board Meeting Intimation for Board Meeting Intimation For Considering And Approving Un-Audited Financial ResultsJan 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 17, 2025
UpdateJan 06, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 03, 2025
Closure of Trading WindowDec 27, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 16, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 09, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 15, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 14, 2024
Announcement under Regulation 30 (LODR)-CessationNov 08, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 07, 2024
Financials Results For The Quarter And Half-Year Ended September 30, 2024Nov 07, 2024
Board Meeting Outcome for Financial Results For The Quarter And Half-Year Ended September 30, 2024Nov 07, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 30, 2024
Board Meeting Intimation for Intimation Of Board MeetingOct 30, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 23, 2024

Technical Indicators

RSI(14)
Neutral
42.93
ATR(14)
Less Volatile
67.97
STOCH(9,6)
Neutral
36.19
STOCH RSI(14)
Oversold
5.95
MACD(12,26)
Bearish
-12.21
ADX(14)
Weak Trend
12.59
UO(9)
Bearish
33.75
ROC(12)
Downtrend And Accelerating
-3.72
WillR(14)
Neutral
-78.02

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
UTI Large & Mid Cap Fund Direct-Growth
0.94%
18768
0.16%
0.06%
UTI Aggressive Hybrid Fund Direct Fund-Growth
0.89%
17007
0.15%
0.07%
UTI Multi Cap Fund Direct-Growth
0.25%
11869
0.25%
0.25%
Samco Flexi Cap Fund Direct - Growth
6.51%
-10000
0.19%
-0.14%
UTI Retirement Fund Direct
0.48%
9672
0.09%
0.06%
Samco Multi Asset Allocation Fund Direct-Growth
0.72%
2377
0.21%
0.72%
UTI Healthcare Fund Direct-Growth
2.53%
2317
0.31%
0.18%
ITI Pharma and Healthcare Fund Direct - Growth
1.08%
-1029
0.04%
-0.16%
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth
1.53%
719
0.05%
-0.06%
Nippon India Nifty 500 Momentum 50 Index Fund Direct-Growth
0.27%
616
0.02%
-0.01%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.23%
481
0.01%
-0.01%
Motilal Oswal Nifty 500 Momentum 50 Index Fund Direct-Growth
0.27%
349
0.02%
-0.01%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.23%
286
0.01%
-0.01%
Edelweiss Nifty500 Multicap Momentum Quality 50 Index Fund Direct-Growth
0.39%
242
0.02%
-0.01%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.23%
202
0.01%
-0.01%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.23%
131
0.01%
-0.01%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.20%
-124
0.01%
0.00%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.02%
83
0.00%
0.00%
UTI Nifty Midsmallcap 400 Momentum Quality 100 Index Fund Direct-Growth
0.30%
79
0.02%
-0.01%
Axis Nifty500 Momentum 50 Index Fund Direct-Growth
0.27%
76
0.02%
0.00%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.23%
58
0.01%
-0.01%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.23%
44
0.01%
-0.01%
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth
0.65%
36
0.02%
-0.02%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.23%
18
0.01%
0.00%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.23%
18
0.01%
-0.01%

About Caplin Point Laboratories

Caplin Point Laboratories Limited is an Indian pharmaceutical company founded in 1990. It develops, produces, and markets generic formulations and branded products globally. The company has manufacturing facilities in India and serves markets in Latin America, Africa, the USA, and the European Union. Caplin Point specializes in various pharmaceutical formulations, including injectables, tablets, capsules, and syrups. The company has expanded through acquisitions, partnerships, and investments in subsidiaries. It has a strong presence in emerging markets and has entered regulated markets like the USA. Caplin Point has invested in research and development, including API development and clinical research. The company has also ventured into e-commerce and has been expanding its product portfolio and manufacturing capabilities.
Chairperson NameC C Paarthipan